Global Human Vaccines Strategic Business Report 2018: Analysis & Forecast 2016-2024 - Market Trends & Issues

DUBLIN, Dec. 7, 2018 /PRNewswire/ --

The "Human Vaccines - Global Strategic Business Reports" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Human Vaccines by the following Product Segments:

    --  Pediatric Vaccines
    --  Adult Vaccines

Company profiles are primarily based on public domain information including company URLs.

The report profiles 66 companies including many key and niche players such as:

    --  ALK
    --  Abell A/S (Denmark)
    --  Altimmune, Inc. (US)
    --  Bavarian Nordic A/S (Denmark)
    --  BiondVax Pharmaceuticals Ltd. (Israel)
    --  Bharat Biotech International Limited (India)
    --  GlaxoSmithKline Plc. (UK)
    --  Hualan Biological Engineering Inc. (China)
    --  Janssen Pharmaceuticals, Inc. (US)
    --  MedImmune (US)
    --  Merck & Co., Inc. (US)
    --  Pfizer Inc. (US)
    --  Sanofi Pasteur SA (France)
    --  Serum Institute of India Pvt. Ltd. (India)
    --  Shanghai BravoBio Co., Ltd. (China)
    --  Seqirus (UK)
    --  SK Chemicals Co., Ltd. (Korea)
    --  Takeda Pharmaceutical Company Limited (Japan)
    --  Zydus Cadila (India)

Key Topics Covered

1. MARKET OVERVIEW & OUTLOOK

    --  Human Vaccines: A Prelude
    --  Human Vaccines Market
    --  A Snapshot
    --  Market Dynamics
    --  Growth Drivers in a Capsule
    --  Developed World: The Key Markets
    --  Emerging Markets: The Future Growth Area
    --  Vaccine Pricing: The Developed
    --  Developing Divide

2. MARKET TRENDS & ISSUES

    --  Prophylactic Pediatric Vaccines
    --  A Mature Market
    --  Emerging Nations Offer Huge Opportunities for Pediatric Vaccine
        Manufacturers
    --  Rising Incidence of Infectious Diseases to Fuel Growth of Anti-Infective
        Vaccines
    --  Novel Vaccines against Emerging Infectious Diseases
    --  Ongoing Developments for a Vaccine against Zika Virus
    --  Sanofi's Dengue Vaccine First-to-Market
    --  Pipeline & Marketed Dengue Vaccine: 2016
    --  Computational Tools Come to Aid in Development of Ebola Vaccines
    --  Vaccine for AIDS
    --  Ongoing Research for HIV Vaccine & Commercial Pipeline
    --  List of Clinical Trial (Phase II) AIDS Vaccines: 2015
    --  Staggering Global Statistics of AIDS
    --  Opportunity Indicator
    --  Vaccination-Autism Link and Other Safety Concerns Thwarted
    --  Threat of Pandemic Rejuvenates Vaccine Market
    --  Influenza Vaccines on a Growing Spree
    --  Influenza Vaccines on the Current Market: 2016
    --  H1N1 Vaccines Hit the Market in August 2009
    --  H1N1 Influenza Vaccines and Manufacturers
    --  Influenza Market Faces Several Challenges
    --  Rising Disease Incidence and Increasing Awareness Drive the Global
        Meningococcal Vaccines Market
    --  Unmet Demand for TB Vaccine
    --  Key TB Vaccine Candidates in the Pipeline: 2016
    --  Need for a Human Vaccine for Leishmaniasis
    --  Economic Factors Hamper Optimal Vaccine Development and Delivery
    --  Increasing Need for Vaccine Promotion in the Developing Regions
    --  Changing Vaccine Needs
    --  Religious Concerns over Immunizing Young Girls against Human
        Papillomavirus
    --  Changing Travel Patterns Increase Demand for Hepatitis B Vaccine
    --  DNA Vaccines: Engineering Growth
    --  Noninjectable Vaccines: Gain without Pain
    --  Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines
    --  Conjugate Vaccines: A Technological Innovation
    --  Hib Vaccines on the Market: 2016
    --  Growing Pricing Pressure
    --  A Major Market Deterrent
    --  Safety Issues Come to the Fore
    --  BioWarfare: Threat Perception and Preparedness
    --  Overview of Potential Bio-Terrorist Agents
    --  Smallpox (Variola Major)
    --  Anthrax (Bacillus Anthracis)
    --  Plague (Yersinia Pestis)
    --  Botulism (Clostridium Botulinum)
    --  Tularemia (Francisella Tularensis)
    --  Tackling Cold Chain Issues
    --  Trade Statistics

3. COMPETITIVE LANDSCAPE

    --  Pfizer Scores Big with Prevnar
    --  Trumenba Shows Promise in Phase III Clinical Trials
    --  GSK Takes Big Leap into the Meningococcal Vaccine Market
    --  Acquired Products Strengthen GSK's Vaccines Sales
    --  The Potential for MenABCWY Vaccine
    --  Sanofi Works on Production Issues to Boost Sales
    --  New Vaccines to Enhance Prospects for Sanofi
    --  Sanofi's Human Vaccine R&D Pipeline
    --  Weaker Sales Drive Merck and Sanofi's European JV Split
    --  Serum Institute to Stir Competitive Landscape in the HPV Vaccine Market

4. PRODUCT OVERVIEW

5. CLINICAL TRIALS IN THE VACCINES MARKET

    --  Inovio and GeneOne to Initiate Phase 1 Human Trial for Zika DNA Vaccine
    --  Takeda Begins Phase2b Trial for World's First Norovirus Vaccine
    --  Bavarian Nordic Announces Positive Results from Phase 1 Trial of RSV
        Vaccine
    --  Investigational Vaccine for P.vivax Malaria Enters Human Trials
    --  Valneva Reports Postive Phase 2 Results for Vaccine Candidate against
        C.difficile
    --  Novavax Announces Positive Phase 2 Clinical Trial Results for RSV-F
        Protein Vaccine
    --  Vical Reports Postive Preclinical Data for CyMVectin CMV vaccine
    --  Profectus BioSciences Receives HHS Contract to Accelerate Ebola Vaccine
        Candidate into Clinical Studies
    --  Inovio and GeneOne to Advance Ebola Vaccine into Phase 1 Trial

6. PRODUCT LAUNCHES/APPROVALS

    --  FDA Approves 2016/17 Formulation of Protein Sciences Corporation's
        Flublok
    --  Sanofi's Dengue Vaccine Approved in Costa Rica
    --  GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line
    --  FDA Approves Seqirus' FLUCELVAX QUADRIVALENT Influenza Vaccine
    --  China Launches HFMD Vaccine
    --  Bharat Biotech Introduces ZIKAVAC Vaccine for Zika Infection
    --  Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection
    --  WHO Accepts Merck's Investigational Ebola Vaccine Application for Review
    --  Sanofi's Dengvaxia Receives Marketing Authorization in Mexico
    --  SK Chemicals Launches Influenza Vaccine SKYCellflu
    --  Sanofi Pasteur Ships First Doses of Fluzone for the US Market
    --  Bharat Biotech Launches Made-in-India ROTAVAC Vaccine

7. RECENT INDUSTRY ACTIVITY

    --  WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's
        Prevnar 13
    --  Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha
        Biotechnics' Facility
    --  Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government
    --  Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated
        Vaccines
    --  WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue
    --  Kaketsuken to Sell Vaccines Business to Astellas
    --  Sanofi and Merck End Joint Venture on Vaccines
    --  GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine
    --  Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA
    --  Bavarian Nordic Enters into License Agreement with Janssen
    --  CSL Rebrands Influenza Vaccines Business as Seqirus
    --  MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease
        Vaccine R&D
    --  GlaxoSmithKline Acquires Novartis' Vaccines Business
    --  Vaxin Changes Name to Altimmune
    --  Takeda Expands Commercialization Agreement with Nanotherapeutics
    --  MedImmune Enters Into License Agreement with Inovio Pharmaceuticals
    --  CSL Completes Acquisition of Novartis' Influenza Vaccines Business
    --  Pfizer to Acquire Meningitis Vaccines from GSK
    --  Pfizer Stops Prevnar Vaccine Sales in China After Government Fails to
        Renew License

8. FOCUS ON SELECT PLAYERS

9. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 63 (including Divisions/Subsidiaries 72)


The United States (22)


Canada (1)


Japan (5)


Europe (14)

    --  France (3)
    --  Germany (2)
    --  The United Kingdom (2)
    --  Spain (1)
    --  Rest of Europe (6)

Asia-Pacific (Excluding Japan) (28)

Latin America (1)


Middle East (1)


For more information about this report visit https://www.researchandmarkets.com/research/xvzs5q/global_human?w=5

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-human-vaccines-strategic-business-report-2018-analysis--forecast-2016-2024---market-trends--issues-300761825.html

SOURCE Research and Markets